Monday, December 23, 2024
Facebook Linkedin Twitter
HomeTagsU.S. Phase I

U.S. Phase I

Healthcare

ImmVira’s MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data

PR Newswire -
ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us